These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 37231821

  • 1. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
    An J, Zhou H, Ni L, Harrision TN, Wei R, Agiro A, Brahmbhatt YG, Oluwatosin Y, Schilling CG, Sim JJ.
    Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
    [Abstract] [Full Text] [Related]

  • 2. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
    Johnson M, Morrison FJ, McMahon G, Su M, Turchin A.
    Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
    [Abstract] [Full Text] [Related]

  • 3. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, Qin L.
    J Am Heart Assoc; 2019 Nov 19; 8(22):e012655. PubMed ID: 31711387
    [Abstract] [Full Text] [Related]

  • 4. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis.
    Jiménez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Enjuanes C, Yun S, Garay A, Moliner P, Corbella M, Jovells-Vaqué S, Alcoberro L, Pons-Riverola A, Ramos-Polo R, Morillas H, Gómez-Hospital JA, Comin-Colet J.
    Eur J Intern Med; 2024 Jul 19; 125():89-97. PubMed ID: 38548513
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, Rogers K, Gallagher M.
    PLoS One; 2019 Jul 19; 14(3):e0213192. PubMed ID: 30845156
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
    Agiro A, An A, Cook EE, Mu F, Chen J, Desai P, Oluwatosin Y, Pollack CV.
    Adv Ther; 2023 Jun 19; 40(6):2886-2901. PubMed ID: 37140706
    [Abstract] [Full Text] [Related]

  • 13. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
    Garlo KG, Bates DW, Seger DL, Fiskio JM, Charytan DM.
    JAMA Netw Open; 2018 Nov 02; 1(7):e183874. PubMed ID: 30646338
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T, Lewis RD, Brown T, Baxter G, de Arellano AR.
    BMC Nephrol; 2023 Mar 09; 24(1):47. PubMed ID: 36890464
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.
    Hundemer GL, Talarico R, Tangri N, Leon SJ, Bota SE, Rhodes E, Knoll GA, Sood MM.
    Clin J Am Soc Nephrol; 2021 Mar 08; 16(3):365-373. PubMed ID: 33608262
    [Abstract] [Full Text] [Related]

  • 18. Adverse effects during treatment with renin-angiotensin-aldosterone system inhibitors; should we stay or should we stop?
    Leon SJ, Carrero JJ.
    Curr Opin Nephrol Hypertens; 2023 May 01; 32(3):290-296. PubMed ID: 36811640
    [Abstract] [Full Text] [Related]

  • 19. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS.
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul 01; 4(3):180-188. PubMed ID: 29726985
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.